The Phase I segment involves a dose escalation study of the therapy as a single agent and in conjunction with oral ...

“We are interested in going after MTAP-/- tumors in non-small cell lung ... good solubility and permeability, and low plasma protein binding. In vivo PK data revealed low clearance and high ...

Protein arginine methyltransferase 5 (PRMT5 ... in various cancers and correlates with poor prognostic outcomes. In MTAP-deleted tumor cells, the accumulating methylthioadenosine (MTA) increases ...

"IDE397 is a potential first-in-class MAT2A inhibitor, that is being advanced as a monotherapy agent in priority MTAP-deletion solid ... MTA-cooperative protein arginine methytranferase 5 ...

Scientists identify a protein on cancer cells that supports the immune response against tumors Sep 13, 2023 Immune and tumor cell 'tug-of-war' controls anti-cancer activity, study finds ...

"This drug is an improvement because it binds to a specific part of the PRMT5 protein in a manner unique to cancer cells with the CDKN2A/MTAP gene deletion," said Mulvaney, who is also an ...

a brain penetrant protein arginine methyltransferase 5 (PRMT5) inhibitor that exhibits methylthioadenosine (MTA) cooperativity resulting in high selectivity for MTAP-deleted cancer cells while ...

The process is described thus: In MTAP null patients, pharmacologically inhibiting MAT2A modulates key protein methylation function, leading to cancer cell death. MTAP-null cells lack the ability ...

BRCA1-associated protein 1 (BAP1), neurofibromatosis type 2 (NF2), methylthioadenosine phosphorylase (MTAP), and argininosuccinate synthetase 1 (ASS1). As the emphasis of the review is on efficacy, ...